Skip to main content
. Author manuscript; available in PMC: 2019 Feb 4.
Published in final edited form as: Vaccine. 2015 Jun 10;33(31):3709–3716. doi: 10.1016/j.vaccine.2015.05.091

Table 1.

Schedule of intramuscular vaccination for The Human and NHP Study Groups in the AVRP Study.

Primary series (months) Booster schedule (months) Study group Month 0 Month 0.5 Month 1 Month 6 Month 12 Month 18 Month 30 Month 42 Month 52
Human 0, 1, 6 12, 18, 30, 42 7-IM AVA Saline AVA AVA AVA AVA AVA AVA N/A
0, 1, 6 18, 42 5-IM AVA Saline AVA AVA Saline AVA Saline AVA N/A
0, 1, 6 42 4-IM AVA Saline AVA AVA Saline Saline Saline AVA N/A
NHP 0, 1, 6 None Human dose AVA No injection AVA AVA No injection No injection Challenge (subset) No injection Challenge
1:5 AVA No injection AVA AVA No injection No injection Challenge (subset) No injection Challenge
1:10 AVA No injection AVA AVA Challenge (subset) No injection Challenge (subset) No injection Challenge
1:20 AVA No injection AVA AVA Challenge (subset) No injection Challenge NA NA
1:40 AVA No injection AVA AVA Challenge NA NA NA NA

The human and NHP studies have been described in detail previously [9,10]. At each time point, humans received either a full dose of AVA or a saline placebo. NHP received diluted doses of AVA (undiluted, 1/5, 1/10, 1/20 or 1/40) at months 0, 1 and 6. Subsets of NHP were challenged at months 12, 30 and 52 [10,11].